AbCellera Biologics WKN: A2QKXS ISIN: CA00288U1066 Kürzel: ABCL Forum: Aktien Thema: Hauptdiskussion

Carl Hansen -- Chief Executive Officer And Carl here, I'll take the second part of the question. So in September of 2023, we made a clear decision to transition from a partnership and platform model to being a clinical stage biotech. That is something that we have done successfully and that we will see come to fruition in Q2 and Q3 of this year as we get our first two CTAs submitted and ultimately get into clinical development. The rationale for simultaneously ramping down the large majority of the partnership business defined as we were running it, let's say, back in 2020, is that you need to make decisions in priority as to where you put your time and attention and your money. And we don't believe that you can walk both those roads simultaneously. So making a decision to be a clinical stage biotech means putting your focus on that objective. Now the one area where we still remain active in partnering and where I think there is some real potential to push forward the science to get interesting programs and possibly to generate significant cash that would help the business is on the TCE front. The deal with AbbVie is in line with that, and we will continue to look for such opportunities going forward.

Steve Willey -- Stifel Financial Corp. -- Analyst Understood. And then congrats on getting the AbbVie collaboration done on the TCE side. Is there a finite number of candidates that are -- that's contemplated under that collaboration? Carl Hansen -- Chief Executive Officer Great questions. First, at the highest level, we are confident in the capabilities of the TC platform that's been maturing. So we feel we're very well positioned. And we are increasingly enthusiastic based not just on internal results, but also on what's happening in the market broadly in the space of TCEs. So I think I've said it before, but the activity is clearly heating up, and that's being driven by some pretty impressive clinical results that show that you can translate some of the success from blood cancers into solid tumors. So we feel we're well-positioned for that. And the collaboration with AbbVie for us is a terrific first collaboration where we've got a meaningful TCE deal, and we're working together on multiple but a small number of targets. And with them, we're excited to explore what we think is some very promising scientific directions for TCEs that we think are gonna be important.

https://www.fool.com/earnings/call-transcripts/2025/02/27/abcellera-biologics-abcl-q4-2024-earnings-call-tra/?source=djc&utm_source=djc&utm_medium=feed&utm_campaign=article&referring_guid=f034da26-791b-4857-8beb-d36d70f8d5c7&mod=mw_quote_news

TD Cowen Keeps Their Buy Rating on AbCellera Biologics (ABCL) TipRanks Auto-Generated Intelligence Newsdesk Feb 28, 2025, 02:55 AM TD Cowen Keeps Their Buy Rating on AbCellera Biologics (ABCL) TD Cowen analyst Brendan Smith maintained a Buy rating on AbCellera Biologics (ABCL – Research Report) yesterday. The company’s shares closed yesterday at $2.92. According to TipRanks, Smith is a 3-star analyst with an average return of 4.1% and a 47.62% success rate. Smith covers the Healthcare sector, focusing on stocks such as Halozyme, Repligen, and Ginkgo Bioworks Holdings. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AbCellera Biologics with a $4.00 average price target. https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-abcellera-biologics-abcl?mod=mw_quote_news

What To Expect From AbCellera Biologics Inc (ABCL) Q4 2024 Earnings Feb. 26, 2025 at 7:55 a.m. ET on GuruFocus.com AbCellera Biologics Inc (ABCL, Financial) is set to release its Q4 2024 earnings on Feb 27, 2025. The consensus estimate for Q4 2024 revenue is $7.58 million, and the earnings are expected to come in at -$0.15 per share. The full year 2024's revenue is expected to be $31.58 million, and the earnings are expected to be -$0.59 per share. More detailed estimate data can be found on the Forecast page. AbCellera Biologics Inc (ABCL, Financial) Estimates Trends Revenue estimates for AbCellera Biologics Inc (ABCL) have remained steady at $31.58 million for the full year 2024. For 2025, revenue estimates have increased from $43.13 million to $43.35 million over the past 90 days. Earnings estimates for AbCellera Biologics Inc (ABCL) have stayed constant at -$0.59 per share for the full year 2024 and at -$0.70 per share for 2025 over the past 90 days. https://www.gurufocus.com/news/2715974/what-to-expect-from-abcellera-biologics-inc-abcl-q4-2024-earnings?r=4bf001661e6fdd88d0cd7a5659ff9748&mod=mw_quote_news

🔜 😎🚀💰💰💰,💰💰$

Und wann geht hier mal was ??

Hoffentlich geht 1 Prozent davon in abcellera rein dann haben wir 5mrd Wert also x5 das wäre Traum

mega :) danke dir

Trump 500 Mrd Ki